These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8583134)

  • 1. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
    Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
    J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
    Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
    Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.
    Poynard T; Bedossa P; Chevallier M; Mathurin P; Lemonnier C; Trepo C; Couzigou P; Payen JL; Sajus M; Costa JM
    N Engl J Med; 1995 Jun; 332(22):1457-62. PubMed ID: 7739681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.
    Hadziyannis S; Bramou T; Makris A; Moussoulis G; Zignego L; Papaioannou C
    J Hepatol; 1990; 11 Suppl 1():S133-6. PubMed ID: 2079571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.
    Schvarcz R; Glaumann H; Weiland O; Norkrans G; Wejstål R; Frydén A
    Scand J Infect Dis; 1991; 23(4):413-20. PubMed ID: 1957127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
    J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.
    Lai MY; Kao JH; Yang PM; Wang JT; Chen PJ; Chan KW; Chu JS; Chen DS
    Gastroenterology; 1996 Nov; 111(5):1307-12. PubMed ID: 8898645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-interferon 2b in the treatment of chronic hepatitis C: interim report of the first multicentre Australian trial.
    Lin R; Liddle C; Farrell GC
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():101-3. PubMed ID: 8359618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy.
    Van Thiel DH; Caraceni P; Molloy PJ; Hassanein T; Kania RJ; Gurakar A; Friedlander L
    J Hepatol; 1995 Nov; 23(5):503-8. PubMed ID: 8583136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C.
    Pérez R; Pravia R; Linares A; Rodríguez M; Lombraña JL; Suárez A; Riestra S; Navascués CA; Rodrigo L
    Gut; 1993; 34(2 Suppl):S139-40. PubMed ID: 8314482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial with interferon alfa 2-b in chronic hepatitis C patients.
    El-Zayadi AR; Selim O; El-Haddad S; Ahdy A
    J Egypt Public Health Assoc; 1994; 69(5-6):335-45. PubMed ID: 17212003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial.
    Fontana RJ; Walsh J; Moyer CA; Lok AS; Webster S; Klein S
    J Clin Gastroenterol; 2002 Feb; 34(2):177-82. PubMed ID: 11782615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial.
    Realdi G; Diodati G; Bonetti P; Scaccabarozzi S; Alberti A; Ruol A
    J Hepatol; 1990; 11 Suppl 1():S68-71. PubMed ID: 2127791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.